{
  "name" : "dacemirror.sci-hub.se_journal-article_ddd0b834779b8e3d4886335816e95053_tao2016.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "Black Phosphorus Nanosheets as a Robust Delivery Platform for Cancer Theranostics",
    "authors" : [ "Wei Tao", "Xianbing Zhu", "Xinghua Yu", "Xiaowei Zeng", "Quanlan Xiao", "Xudong Zhang", "Xiaoyuan Ji", "Xusheng Wang", "Jinjun Shi", "Han Zhang", "Lin Mei" ],
    "emails" : [ "mei.lin@sz.tsinghua.edu.cn", "hzhang@szu.edu.cn", "jshi@bwh.harvard.edu" ],
    "sections" : [ {
      "heading" : null,
      "text" : "C o m m u n iC a tio n\n© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim wileyonlinelibrary.com (1 of 9) 1603276"
    }, {
      "heading" : "Black Phosphorus Nanosheets as a Robust Delivery",
      "text" : ""
    }, {
      "heading" : "Platform for Cancer Theranostics",
      "text" : ""
    }, {
      "heading" : "Wei Tao, Xianbing Zhu, Xinghua Yu, Xiaowei Zeng, Quanlan Xiao, Xudong Zhang,",
      "text" : ""
    }, {
      "heading" : "Xiaoyuan Ji, Xusheng Wang, Jinjun Shi,* Han Zhang,* and Lin Mei*",
      "text" : "Dr. W. Tao, X. Zhu, X. Yu, Dr. X. Zeng, Dr. X. Zhang, Dr. X. Wang, Prof. L. Mei Graduate School at Shenzhen Tsinghua University Shenzhen 518055, China E-mail: mei.lin@sz.tsinghua.edu.cn Dr. W. Tao, X. Zhu, Dr. X. Zeng, Dr. X. Zhang, Dr. X. Wang, Prof. L. Mei School of Life Sciences Tsinghua University Beijing 100084, China Dr. W. Tao, Dr. Q. Xiao, Prof. H. Zhang Shenzhen Key Laboratory of Two-Dimensional Materials and Devices (SKTMD) SZU-NUS Collaborative Innovation Center for Optoelectronic Science and Technology, and Key Laboratory of Optoelectronic Devices and Systems of Ministry of Education and Guangdong Province Shenzhen University Shenzhen 518060, China E-mail: hzhang@szu.edu.cn Dr. W. Tao, X. Ji, Prof. J. Shi Brigham and Women’s Hospital Harvard Medical School 75 Francis Street, Boston, MA 02115, USA E-mail: jshi@bwh.harvard.edu\nDOI: 10.1002/adma.201603276\nultrathin BP nanosheets (NSs) could generate efficient single oxygen and serve as effective photodynamic therapy (PDT) agents.[13] Because of the high extinction coefficient and photo thermal conversion efficiency, the latest reports have shown that there is promising potential for BP quantum dots (QDs) and BP nanoparticles (NPs) as a photothermal therapy (PTT) of cancer.[14,15] The cytotoxicity of BP nanomaterials was also preliminarily studied in these reports, showing no observable toxicity in various cells.[13–16] However, despite the few pio neering studies, the potential of using BPbased nanomaterials as a theranostic delivery platform has not been demonstrated. We expect that the BP NSs may have great possibility to enable efficient loading of theranostic agents, similar to graphene, MoS2, or other theranostic tools, because of the atomically thin 2D structure and relatively large surface area.[4,17] In addition, the biological activities of BPbased nanomaterials are closely related with the fate (e.g., pathway, location, biocompatibility, and biodegradability) of these nanosystems in cancer cells, playing a crucial role in an essential understanding of BP and other emerging 2D nanomaterials in cancer cells. Nevertheless, research on the biological activities of BPbased nanomaterials has also not been reported until now.\nHerein, we designed a theranostic delivery platform based on 2D BP NSs (Figure 1a), studied their biological activities by screening the endocytosis pathways in tumor cells, and finally applied this BP delivery platform in cancer theranostics. BP NSs were synthesized by a modified mechanical exfoliation method from bulk BP and were then functionalized with positively charged polyethylene glycol–amine (PEGNH2) via electrostatic adsorption to improve their biocompatibility and physiological stability. The developed PEGylated BP NSs could load thera nostic agents with high efficiency, such as doxorubicin (DOX) for chemotherapy and cyanine7 (Cy7) for in vivo nearinfrared (NIR) imaging. The endocytosis pathways of PEGylated BP NSs were revealed with a final concentration in lysosomes (Figure 1b). With excellent biocompatibility, DOXloaded PEGylated BP NSs exhib ited enhanced antitumor effects (i.e., photothermal, chemo, and biological responseinduced therapy) both in vitro and in vivo. Therefore, our study demonstrated the promising use of BP as an innovative 2D platform for theranostic delivery and revealed the biological activities of PEGylated BP NSs in cancer cells for the first time, which we expect will provide insights for deep understanding of the emerging 2D nanomaterials.\nIn the first set of experiments, a modified mechanical exfoliation method[13] was adopted to prepare the 2D BP NSs (Figure S1, Supporting Information). Although organic solvents such as Nmethyl2pyrrolidone (NMP) could also lead to good exfoliation efficiency,[11,18] we chose oxygen moleculefree water as the solvent for the mechanical exfoliation of bulk BP into NSs\nThe wave of research on 2D nanomaterials began in 2004, when the first graphene was exfoliated from graphite by a mechanical cleavage technique.[1,2] Over the past decade, an increasing number of monolayer/multilayer 2D nanomaterials with various unique physical and chemical properties have been widely studied and have shown promising applications in optoelectronics, electronics, energy storage and conversion, and biomedicine (e.g., therapeutic delivery, imaging/diagnosis, and biosensors).[3,4] Examples include transitionmetal dichal cogenides (TMDs),[5] covalent–organic frameworks (COFs),[6] hexagonal boron nitride (hBN),[7] metal–organic frameworks (MOFs),[8] layered double hydroxides (LDHs),[9] and black phos phorus (BP).[10] Among the large family of 2D nanomaterials, BP has recently attracted enormous attention due to its distinct structure with corrugated planes of P atoms, which are con nected by strong intralayer PP bonding and weak interlayer van der Waals forces.[11] By breaking down the weak inter layer interactions, the bulk BP can be exfoliated into thin BP sheets with a few layers or even a monolayer. A layerdependent bandgap of 0.3 eV to ≈2 eV, as well as highly accurate optical response properties and an anisotropic charge transport, can be achieved by controlling the structure, leading to fascinating electronic and photoelectronic applications of BP.[12]\nMore recently, a few studies have also shown the potential of BP nanomaterials in biomedical applications. For instance,\nwww.advmat.de\nAdv. Mater. 2017, 29, 1603276\nwww.advancedsciencenews.com\nC o\nm m\nu n\niC a ti\no n\n© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimwileyonlinelibrary.com1603276 (2 of 9)\nvia probe sonication. This solvent will avoid the potential toxicity associated with organic solvents and ensure a clean surface of the obtained NSs for medical use. Due to the electron screening effect, BP NSs would aggregate and precipitate, especially in the presence of salts such as phosphatebuffered saline (PBS) and cell culture medium (Figure S2a,b,e, Supporting Informa tion). Therefore, after centrifugation to remove unexfoliated BP, pure BP NSs were modified by PEGNH2 to enhance their stability in physiological medium. As presented in this study, the PEGylated BP NSs were observed with negligible agglom eration after one week of incubation, showing remarkable sta bility in PBS and cell culture medium (Figure S2a,c,d,f,g, Sup porting Information). The chemical composition and crystal structure of BPPEG NSs were further confirmed by Xray dif fractometry (XRD) and Xray photoelectron spectroscopy (XPS). As shown in Figure S3 (Supporting Information), the BPPEG NSs could be indexed into orthorhombic BP consistent with JCPDS No. 731358.[13,15] No other elements were detected\nwww.advmat.de\nAdv. Mater. 2017, 29, 1603276\nwww.advancedsciencenews.com\nFigure 1. a) Schematic representation of the PEGylated BP theranostic delivery platform. 1: PEGNH2 (surface modification), 2: DOX (therapeutic agents), 3: Cy7NH2 (NIR imaging agents), 4: FA-PEGNH2 (targeting agents), 5: FITC-PEGNH2 (fluorescent imaging agents). b) Screening and summary of the endocytosis pathways and biological activities of PEGylated BP NSs in cancer cells.\nC o m m u n iC a tio n\n© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim wileyonlinelibrary.com (3 of 9) 1603276\nexcept P, C, and O, indicating the high purity of the final product (Figure S4a, Supporting Information). The two strong peaks at ≈129.9 and ≈130.7 eV are the 2p3/2 and 2p1/2 orbitals of zerovalent P in the P 2p spectrum, respectively (Figure S4b, Supporting Information). The weak peak at ≈134.0 eV is the signal of oxidized phosphorus due to the minor degradation on the surface of NSs as previously reported.[13] The hydrodynamic size of BPPEG NSs in PBS and fetal bovine serum (FBS) was further monitored over a span of one week (Figure S5, Sup porting Information). This study further confirmed the stability of BPPEG NSs, as their sizes had no significant change. The zeta potential of BPbased NSs was determined (Figure S6, Sup porting Information), and a relatively reduced surface charge of BPPEG NSs was observed compared with that in a previous study (−10.3 mV in our study vs −35.4 mV),[15] possibly attribut able to the inhibition of the partial oxidation of BP (formation of phosphate groups) via this modified method. Transmission electron microscopy (TEM) and atomic force microscopy (AFM) were used to characterize the surface mor phology of BP NSs pre and postPEGylation (Figure 2a–f). The average size of BP NSs was ≈120 nm (TEM and AFM), and the average height of BP NSs was ≈1–2 nm (AFM). For BPPEG\nwww.advmat.de\nAdv. Mater. 2017, 29, 1603276\nwww.advancedsciencenews.com\nC o\nm m\nu n\niC a ti\no n\n© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimwileyonlinelibrary.com1603276 (4 of 9)\nNSs, the average size was ≈100 nm (TEM and AFM) and the average height was ≈2–3 nm. The minimal decrease in the size of BPPEG NSs was caused by additional sonication during the coating of PEGNH2, and the slight increase in thickness could be attributed to a few amount of PEG that was coated on the NS surface.[19,20] To further demonstrate that PEGNH2 or other functionalized PEGNH2 such as folic acid (FA) PEGNH2 could be successfully coated on the surface of BP NSs, we tested the Fourier transform infrared spectra (FTIR) and scanning transmission electron microscopy (STEM) with energy dispersive Xray spectroscopy (EDS) mapping of ele ments. With an absorption band at ≈2900 cm−1 that was attrib utable to the CH vibration in the PEG segment and character istic stretching vibration at ≈1637–1653 cm−1 from the amide bonding within FA structure, the coating of PEGNH2 or FAPEGNH2 was confirmed (Figure S7, Supporting Informa tion). The feasibility of this coating method was also validated by STEMEDS showing the excellent colocalization of four dif ferent elements (C, O, and N elements from the surface coating FAPEGNH2, and P element from BP) in Figure 2g. Raman spectral analysis, which is an effective method for sample iden tification through detailed rotational and vibrational modes, was performed to verify the structure of PEGylated BP NSs (Figure S8, Supporting Information). The Raman spectra of exfoliated BP NSs showed nearly the same peaks located at ≈363.6, 439.3, and 467.4 cm−1 with those of bulk BP reported previously,[13] which correspond to Ag1, B2g, and Ag2 modes of BP, respectively, suggesting that all prepared NSs did not have structural transformations compared with the corresponding bulk counterpart. A slight shift toward a low wavenumber could be found in PEGylated BP NSs, which could be caused by the slight change in the ultrathin height after PEG (or func tionalized PEG) coating.[21] Similar to the targeting modified PEGNH2 (i.e., FAPEGNH2), the fluorescencemodified PEGNH2 (i.e., FITCPEGNH2) could also be coated on the surface of BP NSs with the same principle. The amount of PEG that was coated on the BP surface was ≈25.8% (w/w %) of the PEGylated BP NSs that was determined by the absorbance of FITClabeled PEG. At the end of this part, the excellent photo thermal properties of BPPEG NSs were tested and well dem onstrated (see the Supporting Information).\nIn the next set of experiments, we tested the use of BPPEG NSs as a novel theranostic delivery platform. Since 2D nano materials such as TMDs, graphene, and their derivatives, which possess a relatively high surface area, have been widely reported as drug carriers to interact with various types of drug molecules,[2,20] the potential loading abilities of BPbased mate rials were well worth the expectation. A solution of BPPEG NSs was mixed with DOX at different feeding ratios (DOX/NSs feeding ratios: 0.6, 1.2, 1.8, 2.4, 3, 3.6, and 4.2) and then stirred overnight. The UV–vis–NIR spectra were measured to calculate the drugloading ratios of these BPPEG NSs after removing excess free DOX molecules (Figure 2h). As the DOX/NSs feeding ratio increased, the loading capacity of DOX increased almost linearly and reached a saturation level at a DOX/NSs feeding ratio of 3 (Figure 2i). Our tested conditions showed that the saturation of DOX loading was tested to be ≈108% and that this was noticeably higher than many conventional NPbased nanodelivery systems with a usual range of ≈10%–30% for\ndrug loading.[22] Moreover, the drugrelease behavior of this novel delivery platform was further investigated in our studies. The DOXloaded NSs (BPPEG/DOX NSs) were dialyzed in PBS solution at different pH values (7.4 and 5.0). The drug release kinetics was determined by collecting the released DOX molecules at different time intervals (Figures S12 and S13, Sup porting Information). ≈33.4% of DOX was released from the DOXloaded NSs at pH 5.0 over a span of 24 h, while ≈15.2% of DOX was released at pH 7.4 in our studies. The cause of this release may be the protonation of the amino group pre sent on the sugar moiety of DOX. An NIR laserinduced local hyperthermia stimulus for the on/off control of the DOX release from BPPEG/DOX NSs could also be observed, leading to a higher drug release of 54.4%. Cy7NH2 could be loaded on the surface of BPPEG NSs using the similar method, and the Cy7loaded NSs used in this study were ≈30.4% (w/w %) of Cy7NH2 on the NS surface (Figure S14, Supporting Information). Moreover, the fluorescence of loaded molecules could be quenched partially by PEGylated BP NSs, indicating strong interactions between drug molecules and BPPEG NSs (Figure S15, Supporting Information).[20]\nAfter confirming the in vitro safety of these PEGylated BP NSs (see the Supporting Information), we next continued to evaluate the in vitro therapeutic effects of PEGylated BP NSs as single photothermal agents and as drug carriers based on their satisfactory performance. HeLa cells were selected as model cancer cells in our following studies. Through MTT assays, we could observe the excellent photothermal therapy (PTT) efficiency of BP NSs and BPPEG NSs in promoting the death of cancer cells, since ≈90% of the cells were killed by only using 50 μg mL−1 BP NSs or BPPEG NSs (while ≈40% for 25 μg mL−1) irradiated with an 808 nm laser at 1.0 W cm−2 for 10 min compared with the cells without treatment (Figure S18a, Supporting Information). The results also demonstrated that PEGylation did not influence the great PTT effect of BP NSs. We subsequently tested the potential of these NSs as a drug delivery platform for cancer chemotherapy with DOX as a model drug. BPPEG/DOX NSs exhibited slightly reduced cytotoxicity compared with free DOX (Figure S18b, Supporting Information), similar to many nanodelivery platforms. These results may be attributed to the relatively slower endocytosis of the nanodelivery platform and additional process of intracel lular DOX release compared with free DOX molecules. In order to promote the therapeutic efficiency and construct specific tar geting delivery systems, we also introduced targeting modified BPPEGFA NSs to act as model nanocarriers for DOX due to the specific binding ability between FA and folate receptor over expressed on many cancer cells, a finding that was also demon strated by many groups as well as by our previous studies.[23] Based on the former studies, quantitative flow cytometry (FCM) was used to further demonstrate the strong FAmediated cancer targeting effect of BPPEGFA NSs. As shown in Figure S19 (Supporting Information), the cellular DOX fluorescence inten sity in HeLa cells after 1 h of incubation with BPPEGFA/DOX NSs was significantly higher than BPPEG/DOX NSs, proving a higher cellular uptake efficiency of BPPEGFA/DOX NSs. Furthermore, the in vitro cellular toxicity of BPPEGFA NSs as photothermal agents and BPPEGFA/DOX NSs as chemo therapy agents was both effectively enhanced compared with\nwww.advmat.de\nAdv. Mater. 2017, 29, 1603276\nwww.advancedsciencenews.com\nC o m m u n iC a tio n\n© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim wileyonlinelibrary.com (5 of 9) 1603276\nthat of BPPEG NSs and BPPEG/DOX NSs, also indicating the good in vitro targeting effect of BPPEGFA NSs. Taken together, the results indicated that PEGylated BP NSs could be utilized to develop a versatile and functionalized delivery plat form and that they are very promising for application in cancer theranostics due to the excellent PTT effect, highloading effi ciency, and especially low toxicity.\nIn the third set of experiments, we performed a biolog ical study of this delivery platform in cancer cells. When the PEGylated BP NSs reached the external milieu of cancer cells through longterm circulation, they could interact with the surface of the cell plasma membrane. The interaction results in the internalization of PEGylated BP NSs through a process termed endocytosis, either clathrindependent or clathrininde pendent.[24] The clathrinindependent pathways are divided into (1) macropinocytosis, (2) caveolaeindependent endocytosis, and (3) caveolaedependent endocytosis. Macropinocytosis is controlled by Rab34, which is considered a biomarker of this process. The caveolaeindependent endocytosis mainly includes flotillin, Arf6, Cdc42, and RhoAdependent endocytosis.[25] Fluorescent imaging agents FITClabeled BPPEG (BPPEG FITC) NSs were employed in the screening of all the possible endocytosis pathways of these NSs. The BPPEGFITC NSs could be internalized by HeLa cells efficiently after 4 h of incu bation (Figure S20, Supporting Information). Moreover, macro pinocytosis and caveolaedependent endocytosis are involved in the entry of the BPPEGFITC NSs into the cells. We observed both colocalization of FITCpositive vesicles with caveolae positive vesicles (Figure 3a) and FITCpositive vesicles with Rab34positive vesicles (Figure 3b). However, no merging of FITCpositive vesicles with clathrin, flotillin, Arf6, Cdc42, or RhoApositive vesicles was found (Figures S21–S25, Supporting Information). These results suggested that the pathways for PEGylated BP NSs occur mainly through caveolaedependent endocytosis and macropinocytosis but not via the clathrin dependent pathway.\nIn the classic endocytosis pathways, nanosystems would be transported to early endosomes, late endosomes soon afterward, and finally lysosomes after being internalized into the cells. Rab5 and EEA1 are widely used markers in early endosomes, whereas Rab7 is used as a marker of late endosomes.[26] We then verified whether our PEGylated BP NSs would be transported via this pathway by detecting the colocalization between caveolae and DsRedRab5 (Figure S26a, Supporting Information) since cav eolaepositive vesicles may deliver BPPEGFITC NSs to early endosomes and then transport them to late endosomes. As pre sented in our studies, BPPEGFITC NSs colocalized perfectly with both DsRedRab5labeled early endosomes and DsRed Rab7marked late endosomes (Figure 3c,d). Furthermore, BP PEGFITC NSs merged well with the lysosomes while the Lyso Tracker was used to mark lysosomes (Figure 3e). These results indicated that BPPEGFITC NSs were taken up by cells through caveolaedependent endocytosis and were then transported to early endosomes and late endosomes, and finally degraded in lysosomes through the classic endocytosis pathway. However, in the macropinocytosis pathway, we did not find that DsRedRab34 colocalized with EEA1labeled early endosomes (Figure S26b, Supporting Information). In contrast, DsRedRab34 colocalized well with DsRedRab7labeled late endosomes (Figure S26c,\nSupporting Information). These data implied that “macropino cytosis (Rab34labeled) → late endosomes (Rab7labeled) → lys osomes” could be a novel endocytosis pathway in the turnover of BPPEGFITC NSs (Figure 1b).\nAfter revealing the endocytosis pathways, we then studied the biological activities of PEGylated BP NSs and focused on autophagy studies since it could sequester most nanomaterials and transport them to lysosomes for degradation.[27] To test the relationship between PEGylated BP NSs and autophagy, LC3II protein and P62 protein were used as autophagy marker pro teins.[28] After incubation with BPPEGFITC NSs for 24 h, the LC3II protein levels were increased and P62 protein levels were reduced in the cells (Figure 3f). Furthermore, autophago somes were significantly increased as shown in Figure 3g, indicating that PEGylated BP NSs could induce autophagy in cancer cells. We further found that P62, which is a marker of sequestosome1 (SQSTM1) and an adapter molecule that selectively recognized and bound the substrates of autophagy, colocalized with BPPEGFITC NSs (Figure S27a, Supporting Information). LC3, which is a marker of autophagosomes, could interact directly with P62/SQSTM1 and capture P62 on the isolation membrane. We observed colocalization between P62positive sequestosome1 and LC3positive autophagosomes (Figure S27b, Supporting Information). As expected, we also perceived that BPPEGFITC NSs containing vesicles merged perfectly with LC3positive autophagosomes (Figure S28a, Sup porting Information). P62positive sequestosome1 selects the target, and LC3positive autophagosomes select P62. Finally, autophagosomes containing BPPEGFITC NSs translocated to fuse with lysosomes for degradation (Figure S28b, Supporting Information). These results advocated P62positive seques tosome1 targeted BPPEGFITC NSs and transported them to LC3positive autophagosomes. The autophagosomes then delivered them to lysosomes. Therefore, in addition to classic endocytosis pathways, autophagy was demonstrated to be involved in the degradation of PEGylated BP NSs.\nSince the PEGylated BP NSs were finally concentrated in the lysosomes for degradation, we may further enhance the thera peutic effect and reduce the dose of PEGylated BP NSs by inhib iting the activities of lysosomes and autophagy. To verify this, Chloroquine (CQ), which is a lysosome tropic agent that pre vents endosomal acidification, blocks the fusion of autophago somes with lysosomes and disrupts lysosomes,[29] was utilized in this part of our studies. We incubated pretreated HeLa cells (30 × 10−6 m free CQ, 24 h incubation) with BPPEG NSs and BPPEGFA NSs at low concentrations (5, 10, and 25 μg mL−1), as well as HeLa cells without pretreated (i.e., free from CQ). After 4 h of incubation with these NSs, HeLa cells were washed with PBS three times, placed into medium, and then irradi ated with an 808 nm NIR laser at 1.0 W cm−2 for 10 min. As expected, the cell viability decreased in the presence of CQ molecules in both BPPEG NSs and BPPEGFA NSs groups compared with the CQfree BPPEG NSs and BPPEGFA NSs groups (Figure 3h). Moreover, free CQ did not show observable toxicity to HeLa cells at our tested concentration. Thus, the ther apeutic effects could be caused by the inhibition of lysosomes and blockade of the fusion between autophagosomes and lys osomes under the effect of CQ, which may reduce the degra dation of PEGylated BP NSs. We further introduced DOXload\nwww.advmat.de\nAdv. Mater. 2017, 29, 1603276\nwww.advancedsciencenews.com\nC o\nm m\nu n\niC a ti\no n\n© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimwileyonlinelibrary.com1603276 (6 of 9)\nNSs for the enhanced therapy of cancer in vitro. Even at a low DOX concentration (5 μg mL−1), the cell viability in groups treated with three factors (NIR, CQ, and DOX) was significantly decreased because of the synergistic effect compared with that in previous groups. Until now, we confirmed the excellent in vitro therapeutic effect of these PEGylated BP NSs, which were attributed to the PTT effect triggered by the NIR irradiation of BPbased NSs, DOXinduced chemotherapy, and CQmediated inhibition of lysosomes and autophagy.\nIn the final set of the experiments, we carried out animal assays to test the possibilities of the PEGylated BP theranostic delivery platform for in vivo application as inspired by so many exciting in vitro results. We first studied the in vivo distribution and tumor accumulation of our BP delivery platform via Cy7 loaded PEGylated BP NSs. After intravenous (i.v.) injection of BPPEG/Cy7 NSs and BPPEGFA/Cy7 NSs at different time frames (1, 12, and 24 h), a wholeanimal NIR imaging approach was utilized to monitor the dynamic change of fluorescent PEGylated BP NSs and their tumor accumulation (Figure 4a and Figure S29, Supporting Information). As presented in the results, Cy7loaded PEGylated BP NSs were distributed throughout the whole body with strong fluorescence signals at 1 h postinjection. At 12 h postinjection, the fluorescence sig nals in both groups decreased due to the clearance of the dye by\nwww.advmat.de\nAdv. Mater. 2017, 29, 1603276\nwww.advancedsciencenews.com\nFigure 3. Endocytosis pathways and biological activities of PEGylated BP NSs. a) CLSM images of HeLa cells incubated with BP-PEG-FITC NSs for 4 h, while caveolae were detected with primary antibodies against caveolae. CLSM images of HeLa cells transfected with b) DsRed-Rab34, c) DsRed-Rab5, and d) DsRed-Rab7 after 4 h of incubation with BP-PEG-FITC NSs. e) For lysosome detection, the HeLa cells were treated with BPPEG-FITC NSs for 4 h and then were treated with Lyso-Tracker probes for 30 min. f) HeLa cells were treated with BP-PEG NSs for 24 h, and then the LC3I/II and P62 protein levels were analyzed by western blotting. Histograms represent the quantitative analysis of LC3 and P62 protein expression performed by Image J, respectively (* P < 0.05, ** P < 0.01). g) EGFP-LC3-transfected HeLa cells were treated with BP-PEG NSs for 24 h, and then quantification of cells with EGFP-LC3 vesicles was performed (** P < 0.01). h) Relative viabilities of HeLa cells after different types of treatment at different BP concentrations (5, 10, and 25 μg mL−1). HeLa cells treated with only BP-PEG NSs or CQ (30 × 10−6 m) was used as control (* P < 0.05, ** P < 0.01, *** P < 0.001).\nC o m m u n iC a tio n\n© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim wileyonlinelibrary.com (7 of 9) 1603276\nwww.advmat.de\nAdv. Mater. 2017, 29, 1603276\nwww.advancedsciencenews.com\nthe body. Meanwhile, more signals were detected in the tumor tissues of the BPPEGFA NSs group than in those of the BPPEG NSs group. At 24 h postinjection, the fluorescence sig nals continued to wane in both groups. However, strong fluo rescence signals could be observed in the tumor tissues of both groups, demonstrating good tumor accumulation of PEGylated BP NSs through the blood circulation and an enhanced perme ability retention (EPR) effect. Moreover, stronger signals of the BPPEGFA/Cy7 NSs group than those of the BPPEG/Cy7 NSs group could further demonstrate the in vivo targeting effect of BPPEGFA NSs, indicating versatile modification such as the targeting effect being very feasible with our PEGylated BP NSs. We further confirmed the good in vivo tumor accumula tion of our PEGylated BP NSs and their versatile ability to be in vivo targeting via the ex vivo study of excised organs at 24 h postinjection (Figure 4b,c). The fluorescence signals remained majorly in the liver and kidney because Cy7 is metabolized throughout the liver (liver Kupffer cells play an important role in the uptake and degradation in extraphagocytosis) and excreted through the kidney. The signals in the lung could be caused by the mechanical retention of largersized NSs in lung capillaries. These biodistribution results were in good agree ment with the excellent long circulation confirmed by pharma cokinetic studies (Figure S30, Supporting Information). Based on the in vivo biological response (see the Supporting Information) and enhanced in vitro therapeutic effects, we car ried out an in vivo antitumor study to validate the enhanced therapy of cancer using our PEGylated BP theranostic delivery platform. BPPEGFA NSs were chosen as the model NSs considering their in vivo targeting effect. The tumorbearing nude mice were treated with Group 1: saline (control), Group 2: CQ (biological responseinduced therapy control), Group 3: DOX (chemotherapy control), Group 4: BPPEGFA/DOX NSs (chemotherapy with delivery platform group), Group 5: BP PEGFA NSs + NIR (PTT group), Group 6: BPPEGFA NSs with i.t.injected CQ + NIR (PTT + biological responseinduced therapy group), and Group 7: BPPEGFA/DOX NSs + NIR with i.t.injected CQ (combined tripleresponse therapy group: chemotherapy + PTT + biological response induced therapy) at the same dose. Groups 5–7 were treated with an 808 nm laser at 1 W cm−2 for 10 min at tumor sites after 24 h injec tion. The tumor volumes were calculated based on the width\nFigure 4. In vivo NIR imaging and antitumor effect of PEGylated BP NSs. a) Time-lapse NIR bio-imaging of nude mice. The tumors were circled with a red-dotted line. G1: BP-PEG/Cy7 NSs group; G2: BP-PEG-FA/Cy7 NSs group. b) NIR bio-imaging of major organs and tumors after i.v. injection at 24 h. H: Heart; LI: Liver; S: Spleen; LU; Lung; K: Kidney; T: Tumor. c) Semi-quantitative biodistribution of BP-PEG/Cy7 NSs and BP-PEG-FA/Cy7 NSs in nude mice measured by the averaged fluorescence intensity of organs and tumors. d) Inhibition of HeLa tumor growth after different treatments (* P < 0.05, ** P < 0.01). Group 1: Saline; Group 2: CQ; Group 3: DOX; Group 4: BP-PEG-FA/DOX; Group 5: BP-PEG-FA + NIR; Group 6: BP-PEGFA + NIR + CQ; Group 7: BP-PEG-FA/DOX + NIR + CQ. e) Morphology of tumors removed from the sacrificed mice in all groups at the end point of study. f) H&E stained histological images of tissue sections from major organs after 14 d of treatment with BP-PEG-FA NSs, BP-PEG-FA NSs + CQ, and BP-PEG-FA/DOX NSs + CQ. Saline was used as a control.\nC o\nm m\nu n\niC a ti\no n\n© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimwileyonlinelibrary.com1603276 (8 of 9)\nwww.advmat.de\nAdv. Mater. 2017, 29, 1603276\nwww.advancedsciencenews.com\nand length of the tumors that were measured every 2 d during the 2 weektreatment (Figure 4d). As displayed in our studies, compared with saline, Groups 3–7 all showed decreasing tumor growth in mice. A better therapeutic effect could be observed in Groups 4 and 5 compared with Group 3 (clinical chemotherapy drug), indicating the promising application of PEGylated BP NSs as drug carriers and PTT agents. Moreover, a significant therapeutic effect could be found in both Groups 6 and 7, dem onstrating that the enhanced antitumor effect of PEGylated BP NSs could be achieved by this combined therapy strategy. Group 7 showed the best therapeutic effect, which was in good agreement with the in vitro toxicity results. CQ seemed to minimally inhibit tumors compared with saline, indicating that the enhanced therapy effect could be caused by inhibiting the degradation of the BPbased NSs. Meanwhile, we found that the body weights of nude mice were not significantly affected, demonstrating that there were no acute side effects in our com bined therapy (Figure S32, Supporting Information). At the end of the 2 weektreatment, all nude mice were euthanized and the tumors were collected, clearly showing the excellent thera peutic effect of our PEGylated BP NSs in the enhanced therapy of cancer (Figure 4e). No tissue damage could be found in the major organs in any experimental group as assessed by H&E staining (Figure 4f). Moreover, no observable side effect or tox icity of our PEGylated BP NSs was found even at a higher dose of 10 mg kg−1 in the in vivo toxicity studies (see the Supporting Information), indicating the promising in vivo application of this BP theranostic delivery platform. However, many more sys tematic studies still need to be performed before future clinical studies of these PEGylated BP NSs, as well as some bio and immunecompatibility studies.[30]\nIn summary, we have demonstrated the promising appli cation of BP NSs as a robust delivery platform for the first time, thus opening an exciting and new research point of 2D BP nanomaterials as a delivery vehicle. Furthermore, we have revealed the biological activities and screened the endocytosis pathways of PEGylated BP NSs in cancer cells for the first time, providing guidance for the essential understanding of BP and other emerging 2D nanomaterials for cancer theranostics. A tripleresponse combined therapy strategy was proposed with these PEGylated BP NSs for cancer treatment. Both in vitro and in vivo experiments verified the safety and enhanced antitumor effect of this platform. Finally, with the flexible modification with functionalized PEGNH2 and great biosafety, these BP NSs could provide a robust platform for cancer theranostics.\nSupporting Information Supporting Information is available from the Wiley Online Library or from the author."
    }, {
      "heading" : "Acknowledgements",
      "text" : "The Administrative Committee on Animal Research in Tsinghua University approved the protocols for all animal assays in this paper. W.T., X.Z. and X.Y. contributed equally to this work. The authors acknowledge the financial support from the National Institutes of Health (NIH) Grants (R00CA160350 and CA200900), Tsinghua Scholarship\nfor Overseas Graduate Studies (2013159), National Natural Science Foundation of China (61435010 and 31270019), Guangdong Natural Science Funds for Distinguished Young Scholar (2014A030306036), Natural Science Foundation of Guangdong Province (2016A030310023 and 2015A030313848), Science and Technology Planning Project of Guangdong Province (2016A020217001), Science and Technology Innovation Commission of Shenzhen (KQTD2015032416270385, JCYJ20150625103619275, JCYJ20150430163009479, JCYJ201603080922 49215 and JCYJ20160301152300347), and Natural Science Foundation of SZU (827/000010). The authors are also grateful for Dr. Ling Ji’s assistance with the blood routine test (BRT) at Peking University Shenzhen Hospital.\nReceived: June 22, 2016 Revised: August 18, 2016\nPublished online: October 31, 2016\n[1] a) K. S. Novoselov, A. K. Geim, S. V. Morozov, D. Jiang, Y. Zhang, S. V. Dubonos, I. V. Grigorieva, A. A. Firsov, Science 2004, 306, 666; b) H. Zhang, ACS Nano 2015, 9, 9451; c) Y. Zhang, T.-T. Tang, C. Girit, Z. Hao, M. C. Martin, A. Zettl, M. F. Crommie, Y. R. Shen, F. Wang, Nature 2009, 459, 820; d) X. Peng, L. Peng, C. Wu, Y. Xie, Chem. Soc. Rev. 2014, 43, 3303; e) X. Li, J. Zhu, B. Wei, Chem. Soc. Rev. 2016, 45, 3145; f) X. Cao, C. Tan, X. Zhang, W. Zhao, H. Zhang, Adv. Mater. 2016, 28, 6167. [2] Y. Chen, C. Tan, H. Zhang, L. Wang, Chem. Soc. Rev. 2015, 44, 2681. [3] a) X. Huang, C. Tan, Z. Yin, H. Zhang, Adv. Mater. 2014, 26, 2185;\nb) R. Kurapati, K. Kostarelos, M. Prato, A. Bianco, Adv. Mater. 2016, 28, 6052; c) G. Yang, C. Zhu, D. Du, J. Zhu, Y. Lin, Nanoscale 2015, 7, 14217. [4] D. Chimene, D. L. Alge, A. K. Gaharwar, Adv. Mater. 2015, 27, 7261. [5] X. Qian, J. Liu, L. Fu, J. Li, Science 2014, 346, 1344. [6] S. Lin, C. S. Diercks, Y. B. Zhang, N. Kornienko, E. M. Nichols,\nY. Zhao, A. R. Paris, D. Kim, P. Yang, O. M. Yaghi, C. J. Chang, Science 2015, 349, 1208. [7] a) T. T. Tran, K. Bray, M. J. Ford, M. Toth, I. Aharonovich, Nat. Nanotechnol. 2016, 11, 37; b) Z. Liu, L. Ma, G. Shi, W. Zhou, Y. Gong, S. Lei, X. Yang, J. Zhang, J. Yu, K. P. Hackenberg, A. Babakhani, J. C. Idrobo, R. Vajtai, J. Lou, P. M. Ajayan, Nat. Nanotechnol. 2013, 8, 119. [8] S. S. Han, J. L. Mendoza-Cortes, W. A. Goddard, Chem. Soc. Rev. 2009, 38, 1460.\n[9] P. J. Sideris, U. G. Nielsen, Z. Gan, C. P. Grey, Science 2008, 321, 113. [10] a) F. Xia, H. Wang, Y. Jia, Nat. Commun. 2014, 5, 4458; b) C. R. Ryder,\nJ. D. Wood, S. A. Wells, Y. Yang, D. Jariwala, T. J. Marks, G. C. Schatz, M. C. Hersam, Nat. Chem. 2016, 8, 597. [11] P. Yasaei, B. Kumar, T. Foroozan, C. Wang, M. Asadi, D. Tuschel, J. E. Indacochea, R. F. Klie, A. Salehi-Khojin, Adv. Mater. 2015, 27, 1887. [12] a) X. Ling, H. Wang, S. Huang, F. Xia, M. S. Dresselhaus, Proc. Natl. Acad. Sci. USA 2015, 112, 4523; b) L. Li, Y. Yu, G. J. Ye, Q. Ge, X. Ou, H. Wu, D. Feng, X. H. Chen, Y. Zhang, Nat. Nanotechnol. 2014, 9, 372; c) S. Das, W. Zhang, M. Demarteau, A. Hoffmann, M. Dubey, A. Roelofs, Nano Lett. 2014, 14, 5733. [13] H. Wang, X. Yang, W. Shao, S. Chen, J. Xie, X. Zhang, J. Wang, Y. Xie, J. Am. Chem. Soc. 2015, 137, 11376. [14] Z. Sun, H. Xie, S. Tang, X.-F. Yu, Z. Guo, J. Shao, H. Zhang, H. Huang, H. Wang, P. K. Chu, Angew. Chem. 2015, 127, 11688. [15] C. Sun, L. Wen, J. Zeng, Y. Wang, Q. Sun, L. Deng, C. Zhao, Z. Li, Biomaterials 2016, 91, 81. [16] N. M. Latiff, W. Z. Teo, Z. Sofer, A. C. Fisher, M. Pumera, Chem. - Eur. J. 2015, 21, 13991. [17] a) M. Orecchioni, R. Cabizza, A. Bianco, L. G. Delogu, Theranostics 2015, 5, 710; b) K. Yang, L. Feng, X. Shi, Z. Liu, Chem. Soc. Rev. 2013, 42, 530.\nC o m m u n iC a tio n\n© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim wileyonlinelibrary.com (9 of 9) 1603276\nwww.advmat.de\nAdv. Mater. 2017, 29, 1603276\nwww.advancedsciencenews.com\n[18] J. Kang, J. D. Wood, S. A. Wells, J. H. Lee, X. Liu, K. S. Chen, M. C. Hersam, ACS Nano 2015, 9, 3596. [19] L. Cheng, J. Liu, X. Gu, H. Gong, X. Shi, T. Liu, C. Wang, X. Wang, G. Liu, H. Xing, W. Bu, B. Sun, Z. Liu, Adv. Mater. 2014, 26, 1886. [20] T. Liu, C. Wang, X. Gu, H. Gong, L. Cheng, X. Shi, L. Feng, B. Sun, Z. Liu, Adv. Mater. 2014, 26, 3433. [21] a) A. Favron, E. Gaufres, F. Fossard, A. L. Phaneuf-L’Heureux, N. Y. Tang, P. L. Levesque, A. Loiseau, R. Leonelli, S. Francoeur, R. Martel, Nat. Mater. 2015, 14, 826; b) X. Zhang, H. Xie, Z. Liu, C. Tan, Z. Luo, H. Li, J. Lin, L. Sun, W. Chen, Z. Xu, L. Xie, W. Huang, H. Zhang, Angew. Chem. Int. Ed. 2015, 54, 3653. [22] a) W. Tao, X. Zeng, J. Wu, X. Zhu, X. Yu, X. Zhang, J. Zhang, G. Liu, L. Mei, Theranostics 2016, 6, 470; b) X. Zeng, W. Tao, L. Mei, L. Huang, C. Tan, S. S. Feng, Biomaterials 2013, 34, 6058. [23] W. Tao, J. Zhang, X. Zeng, D. Liu, G. Liu, X. Zhu, Y. Liu, Q. Yu, L. Huang, L. Mei, Adv. Healthcare Mater. 2015, 4, 1203. [24] S. D. Conner, S. L. Schmid, Nature 2003, 422, 37. [25] S. Mayor, R. E. Pagano, Nat. Rev. Mol. Cell Biol. 2007, 8, 603. [26] G. Sahay, D. Y. Alakhova, A. V. Kabanov, J. Controlled Release 2010, 145, 182. [27] J. J. Li, D. Hartono, C. N. Ong, B. H. Bay, L. Y. Yung, Biomaterials 2010, 31, 5996. [28] a) S. Pankiv, T. H. Clausen, T. Lamark, A. Brech, J. A. Bruun, H. Outzen, A. Overvatn, G. Bjorkoy, T. Johansen, J. Biol. Chem. 2007, 282, 24131; b) Y. Kabeya, N. Mizushima, T. Ueno, A. Yamamoto, T. Kirisako, T. Noda, E. Kominami, Y. Ohsumi, T. Yoshimori, EMBO J. 2000, 19, 5720. [29] a) X. Zhang, Y. Dong, X. Zeng, X. Liang, X. Li, W. Tao, H. Chen, Y. Jiang, L. Mei, S.-S. Feng, Biomaterials 2014, 35, 1932; b) X. Zhang, Y. Yang, X. Liang, X. Zeng, Z. Liu, W. Tao, X. Xiao, H. Chen, L. Huang, L. Mei, Theranostics 2014, 4, 1085. [30] a) M. Orecchioni, D. A. Jasim, M. Pescatori, R. Manetti, C. Fozza, F. Sgarrella, D. Bedognetti, A. Bianco, K. Kostarelos, L. G. Delogu, Adv. Healthcare Mater. 2016, 5, 276; b) M. Pescatori, D. Bedognetti, E. Venturelli, C. Ménard-Moyon, C. Bernardini, E. Muresu, A. Piana, G. Maida, R. Manetti, F. Sgarrella, A. Bianco, L. G. Delogu, Biomaterials 2013, 34, 4395; c) M. J. Sailor, J.-H. Park, Adv. Mater. 2012, 24, 3779."
    } ],
    "references" : [ ],
    "referenceMentions" : [ ],
    "year" : 2016,
    "abstractText" : "Dr. W. Tao, X. Zhu, X. Yu, Dr. X. Zeng, Dr. X. Zhang, Dr. X. Wang, Prof. L. Mei Graduate School at Shenzhen Tsinghua University Shenzhen 518055, China E-mail: mei.lin@sz.tsinghua.edu.cn Dr. W. Tao, X. Zhu, Dr. X. Zeng, Dr. X. Zhang, Dr. X. Wang, Prof. L. Mei School of Life Sciences Tsinghua University Beijing 100084, China Dr. W. Tao, Dr. Q. Xiao, Prof. H. Zhang Shenzhen Key Laboratory of Two-Dimensional Materials and Devices (SKTMD) SZU-NUS Collaborative Innovation Center for Optoelectronic Science and Technology, and Key Laboratory of Optoelectronic Devices and Systems of Ministry of Education and Guangdong Province Shenzhen University Shenzhen 518060, China E-mail: hzhang@szu.edu.cn Dr. W. Tao, X. Ji, Prof. J. Shi Brigham and Women’s Hospital Harvard Medical School 75 Francis Street, Boston, MA 02115, USA E-mail: jshi@bwh.harvard.edu",
    "creator" : "Adobe InDesign CS6 (Macintosh)"
  }
}